Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qingchang Wenzhong tablets for moderately active ulcerative colitis (Phase II, dose-finding, double-blind RCT)
CTR20221842Phase 2Completed
- Sponsor
- Longfengtang
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of qingchang wenzhong tablets in autoimmune colitis, sponsored by Longfengtang. Started Jul 2022; status: completed.
02
Drugs
qingchang wenzhong tablets
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20221842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221842.